Pitolisant for Pediatric Narcolepsy Cataplexy
Quick Facts
What Did The FDA Change For Pediatric Narcolepsy Treatment?
The new approval means clinicians can prescribe pitolisant for excessive daytime sleepiness, cataplexy, or both in pediatric narcolepsy patients aged 6 years and older. Cataplexy is a sudden loss of muscle tone triggered by emotions such as laughter or surprise, and it is one of the most distinctive and disruptive symptoms of narcolepsy type 1.
The pediatric decision was supported by a randomized, double-blind, placebo-controlled trial in children aged 6 to 17 years with narcolepsy with or without cataplexy. In that study, pitolisant produced a greater reduction in Ullanlinna Narcolepsy Scale total score than placebo, a measure that captures excessive daytime sleepiness and cataplexy symptoms.
How Does Pitolisant Work In Narcolepsy With Cataplexy?
Pitolisant is a selective histamine H3 receptor antagonist/inverse agonist. Its exact clinical mechanism is not fully established, but its activity is thought to increase histamine signaling in brain pathways that help regulate wakefulness, making it different from traditional stimulant-based narcolepsy medicines.
A practical distinction for families and clinicians is that pitolisant is not scheduled as a controlled substance in the United States. That does not make it risk-free, but it may reduce some prescribing and storage concerns compared with controlled wake-promoting or stimulant medications.
What Safety Issues Should Families Discuss Before Pitolisant?
In the pediatric trial cited in Contemporary Pediatrics, treatment-emergent adverse events occurred in 31% of pitolisant-treated patients and 34% of placebo-treated patients. The most frequent reported adverse events were headache and insomnia, and investigators described the overall pediatric safety profile as broadly consistent with adult experience.
Prescribing information notes that pitolisant can prolong the QT interval, so clinicians generally avoid it in patients with known QT prolongation or with other QT-prolonging medicines when risk is significant. Dose adjustments may be needed in some hepatic or renal impairment, and the drug is contraindicated in severe hepatic impairment.
Frequently Asked Questions
No. Pitolisant treats symptoms such as excessive daytime sleepiness and cataplexy, but it does not cure narcolepsy or reverse the underlying disorder.
The FDA-approved pediatric indication begins at age 6 years. Use in younger children would require specialist judgment and would not match the approved age range.
References
- Contemporary Pediatrics. FDA approves pitolisant (Wakix) for cataplexy in pediatric narcolepsy. February 17, 2026.
- Harmony Biosciences. Harmony Biosciences receives U.S. Food and Drug Administration approval for Wakix (pitolisant) for the treatment of cataplexy in pediatric narcolepsy. News release. February 17, 2026.
- Dauvilliers Y, Lecendreux M, Lammers GJ, et al. Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial. The Lancet Neurology. 2023;22(4):303-311. doi:10.1016/S1474-4422(23)00036-4